Revenue will grow in high teens' in FY24: Syngene CEO
It was the strongest quarter ever led by the combination of the trends that we saw during the yeargood progress in research services, discovery services and dedicated centres, improved operating performance in our development business and strong uptick in manufacturing services
Syngene International Ltd - 539268 - Machine-Readable Version Of The Financial Results For The Quarter And Year Ended March 31, 2023.
Please find attached the machine-readable version of the financial results for the quarter and year ended March 31, 2023 which were submitted to the Stock exchanges on April 26, 2023 post the conclusion of the Board meeting held April 26, 2023. Syngene International Ltd - 539268 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySyngene International Ltd 2CIN NO.L85110KA1993PLC014937 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 164.00 4Highest Credit Rating during the previous FY CRISILAA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Priyadarshini Mahapatra Designation: Company Secretary and Compliance Officer EmailId: Priyadarshini.Mahaptra@syngeneintl.com Name of the Chief Financial Officer: Sibaji Biswas Designation: Chief Financial Officer EmailId: Sibaji.biswas@syngeneintl.com Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated April 26, 2023, regarding outcome of the Board Meeting and financials for the quarter and year ended March 31, 2023, please find enclosed herewith the copy of newspaper publication of the financials in Financial Express (All India Edition) and Vijayavani (Bengaluru Edition) published on April 28, 2023. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation of audio recording for Q4 FY23 post-earnings call
Syngene International Results Earnings Call for Q4FY23
Conference Call with Syngene International Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript. Q4FY23 Quarterly & FY23 Annual Result Announced for Syngene International Ltd.
Pharmaceuticals company Syngene announced Q4FY23 & FY23 results: Q4FY23: Q4FY23 revenue from operations was up 31% to Rs 994 crore PAT is up 21% to Rs 179 crore FY23: FY23 revenue from operations up 23% to Rs 3,193 crore PAT before exceptional items up 10% to Rs 464 crore The dividend of 50 paisa per share and special additional dividend of 75 paisa per share will be subject to shareholders approval at the Annual General Meeting of the Company. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International, said, “Strong growth in the fourth quarter, added to a positive performance over the course of the year, delivered full-year results ahead of our upgraded guidance. All business divisions delivered growth through the year triggering investment in additional laboratory capacity and new facilities at our campuses in Bangalore and Hyderabad, as well as creating over 1000 new jobs. Manufacturing Services had a particularly strong year, led by our commercial-scale biologics manufacturing business which had a busy fourth quarter supporting our partnership with Zoetis, following successful regulatory inspections by the US, European and UK regulatory authorities. Looking ahead, we are optimistic - despite challenges such as inflation, geopolitical uncertainties and recessionary pressures visible in some regions of the world - that our performance over the last year and the progress we have made on the strategic development of the Company, position us well for the year ahead.” “I am pleased to report a strong performance throughout the year, including our biggest-ever quarter to finish this fiscal year. Our robust business model, broad customer base and strong balance sheet, combined with a tight focus on execution, enabled us to deliver revenue growth of 23% year-on-year, margins at around 30% and increased net cash of Rs 224 crores As a result, in this fiscal year, the Company delivered the highest absolute year-on-year increase in revenue and EBITDA that we have seen in the last 5 years, providing a strong foundation for our future plans” added Sibaji Biswas, Chief Financial Officer, Syngene International Result PDF
Syngene International scales 52-week high on 21% rise in Q4 net profit
Syngene International delivered the highest absolute year-on-year increase in revenue and EBITDA in the last 5 years in FY23. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Shares under Syngene Restricted Stock Unit Long Term Incentive Plan FY 2020 Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and year ended March 31, 2023. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to June 30, 2023.